dystrophic heart failure blocked membrane sealant poloxamer 
dystrophin deficiency causes duchenne muscular dystrophy dmd humans inherited progressive disease striated muscle deterioration frequently involves pronounced cardiomyopathy1 heart failure second leading cause fatalities dmd12 progress towards defining molecular basis disease dmd mostly come studies skeletal muscle comparatively little attention directed cardiac muscle pathophysiological mechanisms involved cardiac myocytes may differ significantly skeletal myofibres; underscored presence significant cardiac disease patients truncated reduced levels dystrophin without skeletal muscle disease3 show intact isolated dystrophin-deficient cardiac myocytes reduced compliance increased susceptibility stretch-mediated calcium overload leading cell contracture death application membrane sealant poloxamer corrects defects vitro vivo administration poloxamer dystrophic mice instantly improved ventricular geometry blocked development acute cardiac failure dobutamine-mediated stress protocol issues relating optimal dosing long-term effects poloxamer humans resolved chemical-based membrane sealants represent new therapeutic approach preventing reversing progression cardiomyopathy heart failure muscular dystrophy 
